Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. (4th December 2019)

• Record Type: Journal Article
• Authors: Noguera-Julian, Antoni; Calzada-Hernández, Joan; Brinkmann, Folke; Basu Roy, Robindra; Bilogortseva, Olga; Buettcher, Michael; Carvalho, Isabel; Chechenyeva, Vira; Falcón, Lola; Goetzinger, Florian; Guerrero-Laleona, Carmelo; Hoffmann, Peter; Jelusic, Marija; Niehues, Tim; Ozere, Iveta; Shackley, Fiona; Suciliene, Elena; Welch, Steven B; Schölvinck, Elisabeth H; Ritz, Nicole; Tebruegge, Marc
• Is Part Of: Clinical infectious diseases. Volume 71:Number 10(2020)
• Page Start: 2561
• Page End: 2569
• Publication Date: 2019-12-04
• Subjects: tuberculosis -- anti–TNF-alpha -- reactivation -- miliary tuberculosis -- children; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz1138
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: In adults, anti–tumor necrosis factor-α (TNF-α) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease, but pediatric data are limited. Methods: Retrospective multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing patients <18 years who developed TB disease during anti–TNF-α therapy. Results: Sixty-six tertiary healthcare institutions providing care for children with TB participated. Nineteen cases were identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin skin test and/or interferon-γ release assay) was performed in 15 patients before commencing anti–TNF-α therapy but only identified 1 LTBI case; 13 patients were already receiving immunosuppressants at the time of screening. The median interval between starting anti–TNF-α therapy and TB diagnosis was 13.1 (IQR, 7.1–20.3) months. All cases presented with severe disease, predominantly miliary TB (n = 14; 78%). One case was diagnosed postmortem. TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB treatment was 50 (IQR, 46–66) weeks. Five of 15 (33%) cases who had completed TB treatment had long-term sequelae. Conclusions: LTBI screening is frequently false-negative in this patient population, likely due to immunosuppressants impairing test performance. Therefore, patients with immune-mediated diseases should be screened for LTBI at the point of diagnosis, before commencing immunosuppressive medication. Children on anti–TNF-α therapy are prone to severe TB disease and significant long-term morbidity. Those observations underscore the need for robust LTBI screening programs in this high-risk patient population, even in low-TB-prevalence settings. Abstract : Children and adolescents on tumor necrosis factor-ɑ inhibitors are prone to severe tuberculosis disease, especially miliary tuberculosis, resulting in significant morbidity. False-negative immunodiagnostic tests are common and a low threshold to initiate targeted investigations is recommended.